<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>345</serviceExecutionTime><Drug id="89742"><DrugName>Org-4419-2</DrugName><DrugSynonyms><Name><Value>Org-4419-2</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>680993-88-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="13880">MSD OSS BV</CompanyOriginator><CompaniesSecondary><Company id="13880">MSD OSS BV</Company></CompaniesSecondary><CrossReferences><SourceEntity id="13880" type="Company"><TargetEntity id="4298331728" type="organizationId">Organon Biosciences BV</TargetEntity></SourceEntity><SourceEntity id="3519" type="ciIndication"><TargetEntity id="G47.33" type="ICD10"></TargetEntity><TargetEntity id="D020181" type="MeSH"></TargetEntity><TargetEntity id="-1851878422" type="omicsDisease"></TargetEntity><TargetEntity id="1563" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="34" type="Action"><TargetEntity id="40" type="Mechanism">alpha2-Adrenoceptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="15" type="Action"><TargetEntity id="213" type="Mechanism">5-HT3 Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="3519">Obstructive sleep apnea</Indication></IndicationsSecondary><ActionsPrimary><Action id="13">5-HT 2 receptor antagonist</Action><Action id="34">Alpha 2 adrenoceptor antagonist</Action><Action id="15">5-HT 3 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1470">Respiratory system agent</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>R</Code><Name>RESPIRATORY SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-23T10:30:13.000Z</LastModificationDate><ChangeDateLast>2014-05-03T00:00:00.000Z</ChangeDateLast><AddedDate>2014-01-20T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="13880" linkType="Company"&gt;NV Organon&lt;/ulink&gt; (now  MSD OSS) was developing Org-4419-2, the maleic acid salt of  &lt;ulink linkID="53508" linkType="Drug"&gt;ORG-4419&lt;/ulink&gt; (the R-enantiomer of   &lt;ulink linkID="3634" linkType="Drug"&gt;mirtazapine&lt;/ulink&gt;), as a tablet formulation for the potential oral treatment of obstructive sleep apnea (OSA), presumably as part of the program with &lt;ulink linkID="23891" linkType="Company"&gt;Cypress Bioscience&lt;/ulink&gt; to codevelop ORG-4419 in combination with other undisclosed drugs for this indication. In July 2005, a phase II study of Org-4419-2 was initiated  [&lt;ulink linkID="1516754" linkType="Reference"&gt;1516754&lt;/ulink&gt;]. However, in June 2006, the companies announced that the results of  recently completed phase IIa trials of Org-4419 did not support continuing a development program evaluating combinations of mirtazapine with another approved drug for OSA  [&lt;ulink linkID="676019" linkType="Reference"&gt;676019&lt;/ulink&gt;] and it is presumed that development of Org-4419-2 for OSA was discontinued at that time.&lt;/para&gt;&lt;para&gt;Organon was also developing  &lt;ulink linkID="44637" linkType="Drug"&gt;S(+)-mirtazapine&lt;/ulink&gt;  for the potential treatment of insomnia.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2005, a phase II, placebo controlled, randomized, double blind, parallel group study (&lt;ulink linkID="132319" linkType="Protocol"&gt;EudraCT2005-000733-37&lt;/ulink&gt;) was initiated in patients (n = 100) with obstructive sleep apnea/hypopnea syndrome, in Spain and Sweden [&lt;ulink linkID="1516754" linkType="Reference"&gt;1516754&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="13880">MSD OSS BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3519">Obstructive sleep apnea</Indication><StatusDate>2006-06-27T00:00:00.000Z</StatusDate><Source id="676019" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13880">MSD OSS BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3519">Obstructive sleep apnea</Indication><StatusDate>2006-06-27T00:00:00.000Z</StatusDate><Source id="676019" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3519">Obstructive sleep apnea</Indication><StatusDate>2005-07-27T00:00:00.000Z</StatusDate><Source id="1516754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13880">MSD OSS BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3519">Obstructive sleep apnea</Indication><StatusDate>2005-07-27T00:00:00.000Z</StatusDate><Source id="1516754" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00018"><Name>5-HT 2 receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00022"><Name>5-HT 3 receptor</Name><SwissprotNumbers><Swissprot>O70212</Swissprot><Swissprot>P23979</Swissprot><Swissprot>P35563</Swissprot><Swissprot>P46098</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00070"><Name>Alpha 2 adrenoceptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=676019" linkType="reference" linkID="676019"&gt;676019&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CN1CCN2c3c(cccn3)Cc4ccccc4[C@@H]2C1.C(=C\C(=O)O)\C(=O)O</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>